Hanmi Pharm is accelerating the development of new obesity drugs. Following efpeglenatide, which has entered the Phase 3 trial in South Korea, Hanmi Pharm’s other new drug candidate has entered the full-scale clinical trial. Furthermore, Hanmi Pharm plans to establish various pipelines, including an oral agent, digital therapy related to obesity prevention and management, and eating disorder treatment.

According to Hanmi Pharm on May 13, the U.S. Food & Drug Administration (FDA) has granted approval for a Phase 1 study of HM15275. HM15275 is a new drug candidate that simultaneously targets glucagon-like peptide-1 (GLP-1)/ glucose-dependent insulinotropic polypeptide (GIP)/glucagon for the treatment of obe